Announcement of New Chief Technology Officer Appointment

株式会社GEXVal
2024年2月1日

GEXVal Inc. (President and CEO: Juran Kato, PhD, Kanagawa, Japan ) is pleased to announce the appointment of Dr. Yusuke Nakayama as the new Chief Technology Officer (CTO).

Dr. Nakayama has over 20 years of experience in drug discovery, with particular expertise in pharmacoinformatics at major pharmaceutical companies. His extensive knowledge spans technology development for pharmacoengineering and data science. His notable achievements include the discovery of drug targets, generation of intellectual property, and translational research. In his new role, Dr. Nakayama will spearhead GEXVal's efforts in drug discovery for rare diseases* and underserved medical conditions lacking effective treatments.

Dr. Kato, President and CEO of GEXVal, commented, "We are delighted to welcome Dr. Nakayama to Team GEXVal. His exceptional expertise will enable us to pursue our mission more strategically and efficiently as we strive to deliver innovative medicines to patients in need."

Dr. Nakayama expressed his enthusiasm, stating, "I am excited to join GEXVal and contribute to the development of next-generation technologies that will drive innovation in the pharmaceutical industry. I look forward to shaping the future of patient care with this forward-thinking company. I am fully committed to dedicating my efforts towards delivering innovative treatments to patients with underserved conditions and rare diseases*, as well as their families, with agility."

References:
*Rare disease: Definition varies between countries.
Japan (<50,000、<4 in 10,000, with population of 128 Million)
--MHLW:  https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000068484.html
--Japan Intractable Disease Information Center:  https://www.nanbyou.or.jp/ 
US   (<200,000、<6.37 in 10,000 with population of 330 Million)
-- US Orphan Drug Act (1983): https://www.congress.gov
--NORD:  https://rarediseases.org/about/
EU   (<250,000、<5 in 10,000 with population of 514 Million)
--Regulation (EC) No 141/2000 European Parliament and of the Council on Orphan Medical Products (1999): https://eur-lex.europa.eu/homepage.html?lang=en
-- Orphanet  https://www.orpha.net/consor/cgi-bin/index.php

有关本事宜请咨询:
Head of Corporate office
Atsushi Sugizaki
info@gexval.com